Bausch Health Companies Inc. Research and Development Arrangement, Contract to Perform for Others, Compensation Earned
Bausch Health Companies Inc. (BHC) reported Research and Development Arrangement, Contract to Perform for Others, Compensation Earned of $76.67 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned · last filed 2014-02-28
- Bausch Health Companies Inc. research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2013-12-31 was $19.27M, a 7.39% decline year-over-year.
- Bausch Health Companies Inc. research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2013-09-30 was $18.84M, a 1.60% decline year-over-year.
- Bausch Health Companies Inc. research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2013-06-30 was $18.33M, a 9.49% decline year-over-year.
- Bausch Health Companies Inc. research and development arrangement, contract to perform for others, compensation earned for the quarter ending 2013-03-31 was $20.23M, a 22.17% decline year-over-year.
- Bausch Health Companies Inc. research and development arrangement, contract to perform for others, compensation earned for fiscal 2013 was $76.67M, a 11.05% decline from fiscal 2012.
- Bausch Health Companies Inc. research and development arrangement, contract to perform for others, compensation earned for fiscal 2012 was $86.19M, a 139.91% increase from fiscal 2011.
- Bausch Health Companies Inc. research and development arrangement, contract to perform for others, compensation earned for fiscal 2011 was $35.93M, a 181.63% increase from fiscal 2010.
- Bausch Health Companies Inc. research and development arrangement, contract to perform for others, compensation earned for fiscal 2010 was $12.76M, a 20.20% decline from fiscal 2009.
| Period end | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 3 month | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 3 month as first filed | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 6 month | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 6 month as first filed | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 9 month | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 9 month as first filed | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 12 month | Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2013-12-31 | $19.27M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $38.11M derived: sum of 2 quarters · filed 2014-02-28 | $56.44M derived: sum of 3 quarters · filed 2014-02-28 | $76.67M 10-K · filed 2014-02-28 | ||||
| 2013-09-30 | $18.84M 10-Q · filed 2013-11-01 | $37.17M derived: sum of 2 quarters · filed 2013-11-01 | $57.40M 10-Q · filed 2013-11-01 | $78.20M derived: sum of 4 quarters · filed 2014-02-28 | ||||
| 2013-06-30 | $18.33M 10-Q · filed 2013-08-07 | $38.56M 10-Q · filed 2013-08-07 | $59.36M derived: sum of 3 quarters · filed 2014-02-28 | $78.51M derived: sum of 4 quarters · filed 2014-02-28 | ||||
| 2013-03-31 | $20.23M 10-Q · filed 2013-05-03 | $41.04M derived: sum of 2 quarters · filed 2014-02-28 | $60.18M derived: sum of 3 quarters · filed 2014-02-28 | $80.43M derived: sum of 4 quarters · filed 2014-02-28 | ||||
| 2012-12-31 | $20.81M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $39.95M derived: sum of 2 quarters · filed 2014-02-28 | $60.20M derived: sum of 3 quarters · filed 2014-02-28 | $86.19M 10-K · filed 2014-02-28 | $64.89M 10-K · filed 2013-02-28 | |||
| 2012-09-30 | $19.14M 10-Q · filed 2013-11-01 | $15.00M 10-Q · filed 2012-11-05 | $39.39M derived: sum of 2 quarters · filed 2013-11-01 | $65.39M 10-Q · filed 2013-11-01 | $48.76M 10-Q · filed 2012-11-05 | $74.07M derived: sum of 4 quarters · filed 2014-02-28 | ||
| 2012-06-30 | $20.25M 10-Q · filed 2013-08-07 | $14.48M 10-Q · filed 2012-08-03 | $46.24M 10-Q · filed 2013-08-07 | $33.76M 10-Q · filed 2012-08-03 | $54.92M derived: sum of 3 quarters · filed 2014-02-28 | $62.61M derived: sum of 4 quarters · filed 2014-02-28 | ||
| 2012-03-31 | $25.99M 10-Q · filed 2013-05-03 | $8.49M 10-Q · filed 2012-05-04 | $34.67M derived: sum of 2 quarters · filed 2014-02-28 | $42.36M derived: sum of 3 quarters · filed 2014-02-28 | $55.73M derived: sum of 4 quarters · filed 2014-02-28 | |||
| 2011-12-31 | $8.68M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $16.37M derived: sum of 2 quarters · filed 2014-02-28 | $29.74M derived: sum of 3 quarters · filed 2014-02-28 | $35.93M 10-K · filed 2014-02-28 | ||||
| 2011-09-30 | $7.69M 10-Q · filed 2012-11-05 | $21.05M derived: sum of 2 quarters · filed 2012-11-05 | $27.25M 10-Q · filed 2012-11-05 | $33.13M derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2011-06-30 | $13.36M 10-Q · filed 2012-08-03 | $19.55M 10-Q · filed 2012-08-03 | $25.43M derived: sum of 3 quarters · filed 2013-02-28 | $26.18M derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2011-03-31 | $6.19M 10-Q · filed 2012-05-04 | $12.07M derived: sum of 2 quarters · filed 2013-02-28 | $12.82M derived: sum of 3 quarters · filed 2013-02-28 | $15.70M derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2010-12-31 | $5.88M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $6.63M derived: sum of 2 quarters · filed 2013-02-28 | $9.50M derived: sum of 3 quarters · filed 2013-02-28 | $12.76M 10-K · filed 2013-02-28 | ||||
| 2010-09-30 | $745.00K 10-Q · filed 2011-11-04 | $455.00K 10-Q · filed 2010-11-05 | $3.62M derived: sum of 2 quarters · filed 2011-11-04 | $6.88M 10-Q · filed 2011-11-04 | $6.10M 10-Q · filed 2010-11-05 | $12.50M derived: sum of 4 quarters · filed 2012-02-29 | ||
| 2010-06-30 | $2.88M 10-Q · filed 2011-08-08 | $2.72M 10-Q · filed 2010-08-06 | $6.13M 10-Q · filed 2011-08-08 | $5.64M 10-Q · filed 2010-08-06 | $11.76M derived: sum of 3 quarters · filed 2012-02-29 | $15.15M derived: sum of 4 quarters · filed 2012-02-29 | ||
| 2010-03-31 | $3.25M 10-Q · filed 2011-05-10 | $8.88M derived: sum of 2 quarters · filed 2012-02-29 | $12.27M derived: sum of 3 quarters · filed 2012-02-29 | $15.52M derived: sum of 4 quarters · filed 2012-02-29 | ||||
| 2009-12-31 | $5.62M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $9.02M derived: sum of 2 quarters · filed 2012-02-29 | $12.27M derived: sum of 3 quarters · filed 2012-02-29 | $15.99M 10-K · filed 2012-02-29 | ||||
| 2009-09-30 | $3.39M 10-Q · filed 2010-11-05 | $6.65M derived: sum of 2 quarters · filed 2010-11-05 | $10.36M 10-Q · filed 2010-11-05 | |||||
| 2009-06-30 | $3.25M 10-Q · filed 2010-08-06 | $6.97M 10-Q · filed 2010-08-06 | ||||||
| 2008-12-31 | $26.51M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |